Slamon 1989: HER2/neu in human breast and ovarian cancer
The follow-up to the 1987 discovery: extra copies of the HER2 gene were found in about a quarter to a third of breast cancers and also in ovarian cancers, they led to overproduction of the HER2 protein, and they marked patients with worse outcomes in both diseases.
Overview
Slamon and colleagues examined HER2/neu gene amplification and expression in 526 breast cancers and 120 ovarian cancers. Amplification was present in about a quarter to a third of the breast tumours and was tightly linked to overexpression of HER2 messenger RNA and protein, so measuring the protein could stand in for measuring the gene. Amplification and overexpression were associated with poorer survival in breast cancer and, for the first time, were shown in ovarian cancer with a similar prognostic effect.
- HER2/neu amplification in about 25 to 30% of 526 breast cancers, correlating with mRNA and protein overexpression.
- HER2 amplification and overexpression also found in ovarian cancers, associated with poorer survival.
- Protein overexpression by immunohistochemistry tracked gene amplification, supporting a tissue test.
This study confirmed HER2 as a prognostic marker and a therapeutic target, showed that immunohistochemistry could identify the patients, and extended the target to ovarian cancer. It set up the clinical development of trastuzumab and the HER2 testing that every breast cancer now receives.
- Retrospective tumour bank study.
- Ovarian findings were smaller in scale and HER2-directed therapy has had less success in ovarian cancer than in breast cancer.
Similar pages
not linked directly; found by shared links- PersonBarbara Bradfield
Shares Dennis J. Slamon, UCLA Jonsson Comprehensive Cancer Center, HER2, HER2-positive breast cancer.
- TreatmentIBI354
Shares HER2, HER2-positive breast cancer, Ovarian cancer.
- CompanyPrecirix
Shares HER2, HER2-positive breast cancer.
- TreatmentTrastuzumab duocarmazine
Shares HER2, HER2-positive breast cancer.
- TreatmentRPH-051
Shares HER2, HER2-positive breast cancer.
- PersonJoaquín Arribas
Shares HER2, HER2-positive breast cancer.
- PersonFei Ma
Shares HER2, HER2-positive breast cancer.
- PersonHelena Earl
Shares HER2, HER2-positive breast cancer.